CSL Behring, the biotech arm of Australia’s CSL Ltd., the multinational blood products company, is to collaborate with US biotech SAB Biotherapeutics Inc. on the development of SAB-185, a polyclonal human antibody product targeted to COVID-19 and manufactured without human plasma donations from recovered patients, adding another avenue of research to CSL’s activities against the infection.
SAB is one of the few companies with experience in developing coronavirus therapeutics, having completed a Phase I study with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?